Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

24 25 Next >

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

August 26, 2022

From Incyte

Via Business Wire

Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

August 24, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

August 23, 2022

From Incyte

Via Business Wire

10 Most Oversold Stocks To Buy In August 2022 ↗

August 10, 2022

Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.

Via Talk Markets

Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance ↗

August 02, 2022

Via Benzinga

Recap: Incyte Q2 Earnings ↗

August 02, 2022

Incyte (NASDAQ:INCY) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled ↗

August 02, 2022

Jakafi sales beat and the company raised its guidance. But another drug fell short.

Via Investor's Business Daily

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Expert Ratings for Incyte ↗

July 28, 2022

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Via Benzinga

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss ↗

May 20, 2022

Via Benzinga

Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

August 02, 2022

From Incyte

Via Business Wire

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

New Indication Approval For Incyte "To Usher New Growth Avenue" ↗

July 21, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗

July 28, 2022

Via Benzinga

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo

July 18, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗

July 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte to Report Second Quarter Financial Results

July 12, 2022

From Incyte

Via Business Wire

Twitter And 3 Other Stocks Insiders Are Selling ↗

July 12, 2022

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them ↗

July 11, 2022

Four pharmaceutical stocks, including three biotech movers, are making big moves.

Via Investor's Business Daily

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

7 Defensive Stocks to Buy for a Bear Market ↗

June 27, 2022

As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market.

Via InvestorPlace

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock ↗

June 14, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗

June 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Tuesday, June 14 ↗

June 14, 2022

CNBC

Via Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy ↗

June 14, 2022

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Via Benzinga

Insights On Incyte Corporation ↗

June 04, 2022

In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million...

Via Talk Markets

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

May 26, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

May 24, 2022

From Incyte

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today